Thermo Fisher Scientific is making significant strides in the Indian biopharma market with the announcement of a new bioprocess design center (BDC) in Genome Valley, Hyderabad. This 10,000 square-foot facility, expected to open early next year, is part of a broader initiative by the company to
Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing
October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing
Recent developments and analyst perspectives have spotlighted Arbutus Biopharma (NASDAQ: ABUS), indicating a promising growth trajectory for this biopharmaceutical company. Chardan Capital's recent decision to raise its target price for Arbutus Biopharma from $4.00 to $4.50 signifies a potential
Rallybio, a small biotech firm, is on a mission to develop treatments for rare diseases, with a particular focus on fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare but potentially fatal disease results from platelet incompatibility between pregnant mothers and their unborn
The recent results of a clinical trial for an oral obesity drug developed by Viking Therapeutics have generated significant interest. The drug has shown promise in early-phase trials, capturing the attention of Wall Street analysts and investors alike. The study results, revealed at a medical